ReviewJournal of neuro-oncology2022
Analysis of factors leading to early termination in glioblastoma-related clinical trials.
Review in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Optical microscopy predictions of focal recurrence in glioblastoma.Science advances · 2026Article
- Early termination of clinical trials enrolling patients with breast cancer: Reasons, determinants, and temporal patterns.Breast (Edinburgh, Scotland) · 2026Article
- Integrating Endovascular Drug Delivery into the Therapeutic Landscape of Glioblastoma.Cancers · 2026Review
- Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations.Drug delivery and translational research · 2026Review
- Approaches in analyzing predictors of trial failure: a scoping review and meta-epidemiological study.BMC medical research methodology · 2026Article
- Characteristics and potential predictors of prematurely terminated interventional clinical trials for ovarian cancer in the ClinicalTrials.gov database.BMC cancer · 2025Article
- Enhancing Patient-Trial Matching With Large Language Models: A Scoping Review of Emerging Applications and Approaches.JCO clinical cancer informatics · 2025Article
- Article
- Why are clinical trials of deep brain stimulation terminated? An analysis of clinicaltrials.gov.World neurosurgery: X · 2024Article
- Analysis of Terminated Hand and Wrist-Related Clinical Trials.Journal of hand surgery global online · 2023Article
- Analysis of the discontinuation and nonpublication of neurooncological randomized clinical trials.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTerminated clinical trials are an inefficient use of financial, patient, and administrative resources. We reviewed ClinicalTrials.gov for completed and terminated clinical trials for glioblastoma multiforme (GBM) and compared reported characteristics of completed and terminated trials to identify factors associated with early trial termination.
methodsClinicalTrials.gov was queried to identify all completed and terminated GBM-related clinical trials. Trial characteristics were examined and the reason for trial termination was determined. Univariate analysis by Pearson's chi-square and a multivariate logistic regression were performed to identify independent predictors of early trial termination.
resultsWe identified 886 completed and terminated GBM-related trials between 2003 and 2020. Of these, 175 (19.8%) were terminated prior to completion. The most common reason for termination was participant accrual difficulties, accounting for 63 (36.0%) terminated trials. Trial termination was associated with trials that reported a primary purpose of diagnosis relative to treatment (OR = 2.952, p = 0.001).
conclusionEarly termination of clinical trials investigating interventions for the treatment of GBM is associated with diagnostic trials relative to therapeutic trials. Patient accrual difficulties are the most commonly identified reason for early trial termination. Predictors of trial termination should be considered when designing GBM-related clinical trials to minimize the odds of early trial termination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.